This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Short Term Rescue Study of Olanzapine

This study has been completed.
Sponsor:
Collaborator:
Eli Lilly and Company
Information provided by (Responsible Party):
Terrence Ketter, Stanford University
ClinicalTrials.gov Identifier:
NCT00186017
First received: September 12, 2005
Last updated: April 12, 2017
Last verified: April 2017
  Purpose

We will assess the effect of olanzapine compared to placebo added to prior treatment on CGI-S in a one-week randomized double-blind study. We will also assess the effect of olanzapine added to prior treatment on CGI-S in an eight-week open treatment study. In addition, we will assess the effect of olanzapine on Young Mania Rating Scale (YMRS), Hamilton and Montgomery-Asberg Depression Rating Scales (HDRS, and MADRS), and Hamilton Anxiety Rating Scales (HARS) in the above paradigms. We will also assess the influence of presentation severity (CGI-S) and polarity (mood elevation versus depression) on olanzapine response. Finally, we will assess safety and tolerability of olanzapine in the above paradigms.

We hypothesize that in diverse mild syndromal and subsyndromal exacerbations of BD in outpatients, randomized double-blind flexibly dosed olanzapine added to prior treatment (including no treatment) will yield greater CGI-S improvement than placebo by the end of one week, and that such improvement will persist over one week of open continuation treatment.


Condition Intervention Phase
Bipolar Disorder Drug: Olanzapine/Zyprexa Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Investigator
Primary Purpose: Treatment
Official Title: Double-Blind Placebo-Controlled Olanzapine Add-on Therapy in the Treatment of Acute Syndromal and Subsyndromal Exacerbations in Bipolar Disorders

Resource links provided by NLM:


Further study details as provided by Terrence Ketter, Stanford University:

Primary Outcome Measures:
  • Mean Change in CGI-BP-OS After 1 Week of Treatment [ Time Frame: Baseline, 1 Week ]
    The Clinical Global Impression - bipolar version - overall severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness at the time of rating 1, normal, not ill; 2, minimally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, very severely ill


Secondary Outcome Measures:
  • Mean Change in YMRS After 1 Week of Treatment [ Time Frame: Baseline, 1 week ]

    The Young Mania Rating Scale (YMRS) scale has 11 items and is based on the patient's subjective report of his or her clinical condition over the previous 48 hours. Responses to each item are summed with a higher score indicating more mania symptoms endorsed.

    Scale:0-60 0=Good 60=Bad


  • Mean Change in MADRS After 1 Week of Treatment. [ Time Frame: Baseline, 1 week ]
    Montgomery-Asberg Depression Rating Scales (MADRS) is a multi-item clinician tool assessing depression. Each item yields a score of 0 to 6. The overall score ranges from 0 to 60. Higher MADRS score indicates more severe depression.

  • Mean Change in Hamilton Anxiety Rating Scales (HAM-A) [ Time Frame: Baseline, 1 Week ]

    The HAM-A was one of the first rating scales developed to measure the severity of anxiety symptoms, and is still widely used today in both clinical and research settings. The scale consists of 14 items, each defined by a series of symptoms, and measures both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical complaints related to anxiety). The HAM-A does not provide any standardized probe questions. Despite this,the reported levels of interrater reliability for the scale appear to be acceptable.

    Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe.



Enrollment: 50
Study Start Date: July 2005
Study Completion Date: June 2010
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Olanzapine/Zyprexa
Olanzapine/Zyprexa 2.5 mg up to 8 per day for 1 week
Drug: Olanzapine/Zyprexa
Olanzapine was started at 2.5-10mg/day and adjusted by 2.5-5mg/day on a daily basis with a maximum dose of 20mg/day.
Other Name: Zyprexa
Placebo Comparator: Placebo
Placebo was taken in the same manner as olanzapine with up to 8 per day for 1 week
Drug: Olanzapine/Zyprexa
Olanzapine was started at 2.5-10mg/day and adjusted by 2.5-5mg/day on a daily basis with a maximum dose of 20mg/day.
Other Name: Zyprexa

Detailed Description:

Development and marketing of new therapies for bipolar disorders (BD) has typically entailed performing double-blind placebo-controlled trials in acute mania maintenance studies and more recently acute depression studies. Such an approach addresses BD primarily in terms of episodes and has the strength of studying levels of pathology sufficiently high to permit detection of treatment effects, and guiding clinicians when they encounter syndromal mood episodes. However, this approach has the important limitation of not addressing an important unmet clinical need, namely the management of subsyndromal symptoms. Indeed, emerging data suggest that in BD subsyndromal symptoms compared to syndromal episodes are far more pervasive. Also such an approach runs the risk of not paying sufficient attention to the disorder construct, in a sense permitting preoccupation with syndromal episodes to carry more importance than the disorder.

We will assess the effect of olanzapine compared to placebo added to prior treatment on CGI-S in a one-week randomized double-blind study. We will also assess the effect of olanzapine added to prior treatment on CGI-S in an eight-week open treatment study. In addition, we will assess the effect of olanzapine on Young Mania Rating Scale (YMRS), Hamilton and Montgomery-Asberg Depression Rating Scales (HDRS, and MADRS), and Hamilton Anxiety Rating Scales (HARS) in the above paradigms. We will also assess the influence of presentation severity (CGI-S) and polarity (mood elevation versus depression) on olanzapine response. Finally, we will assess safety and tolerability of olanzapine in the above paradigms.

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:Patients must meet the following criteria to be eligible to participate in the study:

  • Male or female outpatients, 18 to 70 years of age
  • Female patients of childbearing potential must be using a medically accepted means of contraception
  • Able to communicate intelligently with the investigator, and study coordinator
  • Able to give informed consent
  • DSM-IV diagnosis of bipolar I, bipolar II, cyclothymic disorder or bipolar disorder not otherwise specified, experiencing an acute exacerbation of their illness at Visit 1 (hypomania, subsyndromal depression, hypomania and subsyndromal depression, depression and hypomania, or depression if diagnosed with bipolar II) as verified by SCID-I/P
  • CGI-BP Overall Severity score greater than or equal to mildly ill at Visit 1
  • Must have been on prior medications for at least 2 weeks (6 weeks for fluoxetine) immediately prior to study entry

Exclusion Criteria:Patients may not participate in the study if they have any of the following conditions:

  • Pregnant, nursing, or intending to become pregnant during the study
  • Serious, unstable illnesses including hepatic, renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic, or hematologic disease such that hospitalization for the disease is anticipated within 3 months or death is anticipated within 3 years.
  • A history of seizure disorder
  • History of leukopenia without a clear and resolved etiology.
  • DSM-IV substance (except nicotine or caffeine) dependence within the past month
  • Judged clinically to be at serious suicidal risk
  • Participation in clinical trial of another investigational drug within 1 month (30 days) prior to study entry.
  • Treatment with an injectable depot neuroleptic within less than one dosing interval between depot neuroleptic injections prior to study entry
  • Treatment resistance, non-response, or intolerability with olanzapine by the investigator's judgment
  • Treatment with clozapine within 3 months prior to study entry
  • Treatment with remoxipride within 6 months (180 days) prior to study entry
  • Treatment with an oral antipsychotic within 2 days prior to study entry
  • A course of ECT (electroconvulsive therapy) in the preceding 4 weeks
  • Excluded mood symptoms noted in Table 1 [of protocol]
  • Unstable thyroid pathology and treatment-initiated or altered within the past 3 months
  • Meet criteria for antisocial personality disorder
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00186017

Locations
United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Eli Lilly and Company
Investigators
Principal Investigator: Terence Arthur Ketter Stanford University
  More Information

Additional Information:
Responsible Party: Terrence Ketter, Professor, Stanford University
ClinicalTrials.gov Identifier: NCT00186017     History of Changes
Other Study ID Numbers: 79897
F1D-US-X279 ( Other Grant/Funding Number: Eli Lilly )
Study First Received: September 12, 2005
Results First Received: December 21, 2016
Last Updated: April 12, 2017
Individual Participant Data  
Plan to Share IPD: No

Additional relevant MeSH terms:
Bipolar Disorder
Bipolar and Related Disorders
Mental Disorders
Olanzapine
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents

ClinicalTrials.gov processed this record on June 28, 2017